LFCR Stock — Lifecore Biomedical Inc.

Lifecore Biomedical Inc. (LFCR)

Updated October 16, 2026.

LFCR is a Stock. Total return is -50.0% over the past 30.7 years, 1937.1 points behind SPY at 1887.1%.

Lifecore Biomedical is an integrated contract development and manufacturing organization serving the pharmaceutical and medical device industries, providing services including development, aseptic fill-and-finish manufacturing, and analytical support for injectable products across multiple modalities, as well as manufacturing pharmaceutical-grade hyaluronic acid for ophthalmic and orthopedic applications. The company operates manufacturing facilities in the United States and Europe and serves customers globally. Information on the company's dividend distribution practices is not currently available.

LFCR performance versus SPY

Price and return data through 2026-10-16.

Total return is -50.0% over the past 30.7 years, 1937.1 points behind SPY at 1887.1%. Over the past year its total return — price change plus distributions reinvested — is -2.3%. Its deepest 1-year drawdown was 58.5%.

LFCR key facts

Asset type

Stock

Asset class

Equity

Inception date

02/15/1996

Distribution frequency

None

Last close

$6.38 (as of 2026-10-16)

Market cap

$241,839,297

Average volume

1422595.0

Beta

0.979

Payout ratio

0.0%

Forward P/E

8.673

EPS

$-1.27

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LFCR risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 58.5%.

Who may consider LFCR — and who may not

It is a weaker fit for investors who need monthly cash flow (LFCR does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LFCR

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions